Arcutis Biotherapeutics, Inc. (ARQT) Tops Q4 EPS by 5c, provides guidance

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q4 EPS of $0.13, $0.05 better than the analyst estimate of $0.08. Revenue for the quarter came in at $129.5 million versus the consensus estimate of $111.14 million.

Financial Guidance
The Company raised net product revenue guidance for the full year 2026 from between $455 million and $470 million to between $480 million and $495 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• Obsidian Energy Increases Syndicated Credit Facility